Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

abionic

Explore full profile

Uses highly advanced technologies to provide the medical profession with a diagnostic tool customized to give patients' profiles

Epalinges, SwitzerlandFounded 2010Biotech & Life Sciences
Valuation $100–250M Last recorded · 2018
Revenue $10–50M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for abionic and the history behind them.

About abionic

Abionic is a Swiss-based startup that specializes in rapid in vitro diagnostic (IVD) testing. This means they provide tests that can detect diseases or other conditions using samples like blood or tissue that have been taken from the human body. Their innovative approach uses proprietary nanofluidic technology, which involves manipulating small amounts of fluids on a nanoscale, to analyze up to 14 parameters simultaneously from just one drop of blood. This process takes about 5 minutes, providing healthcare professionals with quick, laboratory-quality results.

The company's main product is the abioSCOPE platform, which offers cost-effective, ultra-rapid panel solutions at the point of care. This means that tests can be conducted and results can be obtained right at the patient's bedside, rather than having to send samples to a lab and wait for results. This rapid turnaround time is a significant advantage in urgent care situations where time is of the essence.

Abionic's business model is based on selling these diagnostic tests to healthcare professionals. Their clients include hospitals, clinics, and other healthcare facilities. They operate in the healthcare market, specifically in the in vitro diagnostics sector. The company makes money by selling their testing kits and the proprietary technology that goes with them.

In summary, Abionic is a healthcare technology startup that provides rapid, accurate, and easy-to-use diagnostic tests to healthcare professionals. Their innovative use of nanofluidic technology and their ability to deliver results at the point of care sets them apart in the in vitro diagnostics market.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2010
Headquarters
Epalinges, Switzerland
Employees
30
Open positions
None listed
Dealroom signal
70.8/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices, Health Platform
Sector
Biotech & Life Sciences, Biotechnology, Patient Care, Health Diagnostics, Spinout, Clinical Decision Support, Physician Support Tools
Technology
Deep Tech, Nanotech
Business model
Manufacturing
Client focus
b2b

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANT✓Other financing Jun 2023 $69K — Branchenverband Swiss Medtech ↗
SERIES C✓Equity / VC Mar 2018 $18M $73M Philippe Glatz · Verve Ventures · ZKB - Zürcher Kantonalbank · Jean-Bernard ↗
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023
2022
2021
2020 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

abionic website traffic

Latest recorded traffic for abionic is 1K monthly website visits, up 1566.7% over the last three months. abionic's team declined 6.3% over the past year.

Latest monthly visits1K 3-month web change+1566.7% 1-year team growth-6.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

19 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Venture Kick
  • Fondation FIT
  • Branchenverband Swiss Medtech

Series B and later9 investors entered at this stage

  • Pierangelo Bottinelli
  • Philippe Glatz
  • Verve Ventures
  • ZKB - Zürcher Kantonalbank
  • Jean-Bernard
  • Peter Brabeck-Letmathe
  • Arkady Volozh
  • Nelson Dumas
  • Nest Collective Foundation

Other known investors7 additional known investors

  • EPFL Swiss Federal Polytechnic School of Lausanne
  • Swissnex
  • Blue Ocean Ventures
  • EFI Lake Geneva Ventures
  • FONGIT
  • VentureLab
  • Yves Latour
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇭 Switzerland87%
🇫🇷 France13%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about abionic on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See abionic’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.